Rapid Influenza Diagnostic Tests Market
Market Study on Rapid Influenza Diagnostic Tests: Influenza A+B Testing to Account for Major Market Share
Rapid Influenza Diagnostic Tests Market Segmented By Immunochromatographic Assays, Immunofluorescence Assays, Nucleic Acid Amplification Test principle with Influenza A Test, Influenza B Test, Influenza A+B Test Type by Throat Swab, Nasal Wash, Nasopharyngeal Aspirate Sample Type
The global rapid influenza diagnostic tests market was valued at US$ 800.8 Mn in 2020, and is expected to register a CAGR of 8.7% over the forecast period (2021-2031). As per Persistence Market Research’s projections, immunochromatographic assays hold a substantial 66.8% share in the overall market.
In 2020, the rapid influenza diagnostic testing accounted for approx. 3.4% of the overall infectious disease diagnostics market, due to sudden increase in the number of infectious diseases and viral infections across the world.
Rapid Influenza Diagnostic Tests Market Size (2020)
US$ 800.8 Mn
Projected Market Value (2031)
US$ 2 Bn
Share of Top 5 Countries
Find Out More about the Report Coverage
- Thermo Fisher Scientific
- Quidel Corporation
- F. Hoffmann-La Roche AG
- Abbott Laboratories
- Becton Dickinson and Company
- Danaher Corporation
- Meridian Bioscience
- bioMérieux SA
- Luminex Corporation
- Siemens Healthineers AG
- GenMark Diagnostics
- Sekisui Diagnostics
- LLC altona Diagnostics GmbH
- SA Scientific
- ELITech Group
Demand Analysis of Rapid Influenza Diagnostic Tests from 2016 to 2020 Vs Market Outlook for 2021 to 2031
The rapid influenza diagnostic tests market was valued at US$ 800.8 Mn in 2020.
Rapid Influenza Diagnostic Tests (RIDT) are used to diagnose and treat highly contagious infections spread through the air or physical contact. RIDT has a number of benefits, including accurate detection and diagnosis of influenza and other viral diseases.
Growing awareness of the necessity of early viral disease detection among the global population is one of the primary drivers for rapid influenza diagnostic test demand. Organisations are taking steps to promote early detection in order to reduce and eliminate disease-related deaths. Early diagnosis aids medical professionals and patients in making key medical decisions regarding treatment and support. There are numerous benefits to receiving an accurate and early diagnosis after recognising cognitive symptoms associated with a medical issue.
Advanced technologies enable highly effective and precise influenza diagnostics, opening up a large commercial opportunity in the market. For example, a real-time molecular test called Reverse Transcription-Polymerase Chain Reaction (RT-PCR) can detect influenza genetic material. Furthermore, due to speedy results and convenience of specimen collection, continuous developments in Rapid Influenza Diagnostic Testing (RIDT) have made this method an effective one for diagnosis.
The global market for rapid influenza diagnostic tests is expected to register a high CAGR of 8.7% over the forecast period (2021-2031).
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
What are the Key Opportunities for Providers of Rapid Influenza Diagnostic Tests?
The influenza diagnostics market is pretty competitive. Furthermore, technological improvements and innovations in providing quick, precise, and low-cost disease diagnostics are a crucial factor creating an opportunity for market competitors.
Strategic activities such as securing CLIA waiver approvals for influenza assays and test kits will aid companies in establishing their footprint across numerous foreign markets. In addition, robust distribution network and global presence will provide future growth potential.
Continuous strategic initiatives by prominent players to develop and launch advanced products are anticipated to significantly support market growth.
- In March 2021, Luminex Corporation said that it had submitted an Emergency Use Authorization application to the US Food and Drug Administration for its new multi-analyte respiratory panel, which combines Flu A/B, respiratory syncytial virus (RSV), and SARS-CoV-2 targets.
- In October 2020, the FDA emergency approval to the GenMark test, which screens for flu, coronavirus, and other infections. The test searches for over 20 different viruses and bacteria at the same time, including coronavirus.
- In October 2018, The US Food and Drug Administration (FDA) certified Abbott's next-generation influenza A and B and Strep A molecular assays for use in point-of-care testing.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Which Factors are Restraining Demand for Rapid Influenza Diagnostic Tests?
Main factors that influence the results of rapid influenza diagnostic kits are sensitivity and specificity. The antigenic heterogeneity of influenza viruses is the primary cause for the test's complexity. As a result, the sensitivity and specificity of influenza diagnostic tests vary, which can affect the final test results.
False-negative results are more prevalent than false-positive results as a result, especially during peak influenza seasons, which is a primary factor restricting demand for rapid influenza diagnostic kits to some extent.
Stringent regulatory guidelines for approval of new kits may act as a market restraint. Global regulatory policies, cGMP, and inspection regimes tightening and supply chain security issues across emerging countries have a large impact on the availability and cost of final products, thereby negatively impacting rapid influenza diagnostic tests market growth.
Explore Persistence Market Research’s expertise in promulgation of the business !
Why is the U.S. One of the Largest Markets for Rapid Influenza Diagnostic Tests?
In 2021, the U.S. dominated the North American market for rapid influenza diagnostic kits with more over 80% of the market share. Due to an increase in influenza prevalence and rise in hospitalisation, the U.S is expected to reflect similar market trends over the projection timeframe. Furthermore, due to its large patient population, the U.S. holds a significant market share in the North American region.
Why is Germany Leading the Market for Rapid Influenza Diagnostic Tests in Europe?
Germany dominates the European market for rapid influenza diagnostic tests with over 20% market share owing to rise in prevalence of influenza, favourable government initiatives, presence of major players, and state-of-art facilities in the region, which would help the market grow even more.
What Makes China and India Emerging Markets for Rapid Influenza Diagnostic Tests?
China is an emerging market for rapid influenza diagnostic tests due to advanced healthcare infrastructure, favourable policies, and insurance and diverse organisations, as well as a number of international companies.
Furthermore, growth in influenza research for diagnostic technologies is a major factor attributed to the growth of the influenza diagnostics market in the country.
Increasing number of influenza cases, rising aging population, growing demand for rapid disease diagnosis, and increasing focus of key vendors in the diagnostics market are major factors attributed to the growth of the market in India. Currently, India holds nearly 3% of the global market share for rapid influenza diagnostic equipment.
Why is Popularity of Immunochromatographic Assays High?
By principle, immunochromatographic assays are set to hold a high share of 66.8%, expanding at 6.1% CAGR over the forecast period. Primary factors that support segment growth are good sensitivity and excellent specificity as compared to other laboratory immunoassays.
Which Rapid Influenza Diagnostic Test Type is Most in Demand?
By test type, the Influenza A+B test is expected to hold over 79% of the market share, and is expected to continue growing at a high pace due to benefits such as simple-to-use and rapid diagnosis.
Nasopharyngeal Swabs - the Go-to Method for Rapid Influenza Diagnostic Testing?
By sample, nasopharyngeal swabs are expected to hold over 31% of the market share, and nasopharyngeal aspirate is the second-leading segment that accounts for 27.5% share in the market.
Impact of COVID-19
Rising global burden of infectious diseases, such as influenza and other diseases, has boosted demand for infectious disease diagnosis products. The latest coronavirus (COVID-19) outbreak has wreaked havoc in a number of countries around the world.
Both viruses, when compared to influenza, have a similar illness presentation, in that, they both induce respiratory problems. Furthermore, both are spread via touch, droplets, and fomites. COVID-19 patients are frequently misdiagnosed with influenza in the early stages of the disease. However, it was quickly discovered that in the case of COVID-19 and influenza, factors such as immunity, age group, transmission rate, immunization, and a few others are radically different.
As a result of the recognition of the differences between these two diseases, demand for influenza kits has returned to normal, and the necessity for a comprehensive strategy for diagnosis and treatment has become more critical in the fight against the COVID-19 pandemic.
The market for rapid influenza diagnostic testing is characterised as a consolidated space. Some of the dominant players in the industry include Quidel Corporation, Abbott Laboratories, Luminex Corporation and Becton, Dickinson & Company.
Companies continue to dominate the market for rapid influenza diagnostic tests with new product launches to enhance their rapid influenza diagnostic test product portfolios and customer base. They are also focusing on acquiring regulatory approvals to launch their products across nations.
- In September 2021, The CE Mark was granted to Diasorin Molecular's new COVID-19/Influenza multiplex test.
- In February 2021, the U.S. Food and Drug Administration (FDA) granted emergency use authorization for the Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit by Thermo Fisher Scientific.
- In September 2020, Roche announced that the FDA has granted the cobas® SARS-CoV-2 & Influenza A/B Test for use on the cobas® 6800/8800 Systems an Emergency Use Authorization (EUA).
Similarly, recent developments related to rapid influenza diagnostic instruments and tests have been tracked by the team at Persistence Market Research, which are available in the full report.
Rapid Influenza Diagnostic Tests Industry Report Scope
Historical Data Available for
US$ Mn for Value
Key Regions Covered
Key Countries Covered
Key Market Segments Covered
Key Companies Profiled
Available upon Request
Key Segments Covered in Rapid Influenza Diagnostic Tests Industry Research
- Immunochromatographic Assays
- Immunofluorescence Assays
- Nucleic Acid Amplification Test (NAAT)
By Test Type
- Influenza A Test
- Influenza B Test
- Influenza A+B Test
- Throat Swab
- Nasal Swab
- Nasal Aspirate
- Nasal Wash
- Nasopharyngeal Swab
- Nasopharyngeal Aspirate
- Nasopharyngeal Wash
By End User
- Diagnostic Centres
- Nursing Homes
- Office-based Settings
- Urgent Care Centres
- Retail Pharmacy Clinics
- Schools & Universities
- Public Health Camps
- FAQs -
The global rapid influenza diagnostic tests market is worth US$ 869.4 Mn, and is set to expand 2.3X over the next ten years.
The market for rapid influenza diagnostic instruments is expected to top US$ 2 Bn by 2031, while expanding at a CAGR of 8.7%.
From 2016-2020, the market for rapid influenza diagnostic tests expanded at the rate of 6.1.
Increasing adoption of rapid influenza testing kits, growing awareness for early detection using specific diagnostic tests, development of CLIA-waived POC molecular influenza tests, and shifting focus from centralized laboratories to decentralized point-of-care are some of the key trends being witnessed in this marketplace.
The U.S., Canada, Japan, Germany, and Australia are expected to drive most demand for rapid influenza diagnostic tests.
North America is one of the key markets for rapid influenza diagnostic tests. The U.S. is expected to account for more than 85% share of the North American market.
Demand of rapid influenza diagnostic tests in Europe is expected to register a growth rate of 7.8% over the decade.
Demand for rapid influenza diagnostic tests in South Asia is expected to register a CAGR of 9.6% through 2031.
Demand of rapid influenza diagnostic tests in China is expected to surge at 12.3% CAGR over the forecasted period.